Are We Heading Toward a Recession?
Fears of a recession in 2025 grew at the end…
Sell
44
CVAC Quote, Financials, Valuation and Earnings
Last price:
$3.49
Seasonality move
:
-9.32%
Day range:
$3.40 - $3.59
52-week range:
$2.37 - $5.28
Dividend yield:
0%
P/E ratio:
4.29x
P/S ratio:
1.33x
P/B ratio:
1.08x
Volume:
619.1K
Avg. volume:
662.4K
1-year change:
16.44%
Market cap:
$781.3M
Revenue:
$579.3M
EPS (TTM):
$0.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$3.8M | -$0.21 | -69.1% | -50.99% | $6.24 |
|
BAYRY
Bayer AG
|
$11.1B | $0.11 | -1.2% | -32.26% | $8.76 |
|
BNTX
BioNTech SE
|
$863.4M | -$0.65 | 11.73% | -18.87% | $136.23 |
|
FMS
Fresenius Medical Care AG
|
$5.8B | $0.52 | 12.44% | 40.55% | $26.67 |
|
MKKGY
Merck KGaA
|
$6.1B | $0.52 | 6.53% | 72.9% | $37.10 |
|
SMMNY
Siemens Healthineers AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$3.47 | $6.24 | $781.3M | 4.29x | $0.00 | 0% | 1.33x |
|
BAYRY
Bayer AG
|
$6.80 | $8.76 | $26.7B | -- | $0.03 | 0.46% | 0.53x |
|
BNTX
BioNTech SE
|
$92.77 | $136.23 | $22.3B | 191.55x | $0.00 | 0% | 7.52x |
|
FMS
Fresenius Medical Care AG
|
$28.39 | $26.67 | $16.7B | 24.86x | $0.64 | 2.26% | 0.80x |
|
MKKGY
Merck KGaA
|
$27.84 | $37.10 | $60.5B | 20.08x | $0.50 | 1.8% | 2.64x |
|
SMMNY
Siemens Healthineers AG
|
$26.44 | -- | $59.3B | 26.45x | $0.50 | 3.79% | 2.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVAC
CureVac NV
|
-- | 1.762 | -- | 6.10x |
|
BAYRY
Bayer AG
|
55.28% | -0.474 | 212.48% | 0.71x |
|
BNTX
BioNTech SE
|
1.53% | 1.910 | 1.45% | 9.86x |
|
FMS
Fresenius Medical Care AG
|
32.23% | 0.593 | 46.71% | 0.93x |
|
MKKGY
Merck KGaA
|
24.12% | 0.487 | 15.88% | 0.67x |
|
SMMNY
Siemens Healthineers AG
|
0.59% | 1.002 | 0.2% | 0.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
BAYRY
Bayer AG
|
$6.4B | $3.8B | -5.26% | -7.79% | -0.82% | $4.2B |
|
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
|
FMS
Fresenius Medical Care AG
|
$1.2B | $401.7M | 3% | 4.05% | 7.1% | $18M |
|
MKKGY
Merck KGaA
|
$3.3B | $1.3B | 7.21% | 9.8% | 16.02% | $752.1M |
|
SMMNY
Siemens Healthineers AG
|
$2.4B | $888.1M | 10.84% | 11.11% | 14.11% | $197.2M |
CureVac NV vs. Competitors
-
Which has Higher Returns CVAC or BAYRY?
Bayer AG has a net margin of 68.44% compared to CureVac NV's net margin of -2.86%. CureVac NV's return on equity of 21.3% beat Bayer AG's return on equity of -7.79%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M BAYRYBayer AG51.21% -$0.09 $74.4B -
What do Analysts Say About CVAC or BAYRY?
CureVac NV has a consensus price target of $6.24, signalling upside risk potential of 78.76%. On the other hand Bayer AG has an analysts' consensus of $8.76 which suggests that it could grow by 28.82%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV2 2 0 BAYRYBayer AG1 1 0 -
Is CVAC or BAYRY More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bayer AG has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.066%.
-
Which is a Better Dividend Stock CVAC or BAYRY?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bayer AG offers a yield of 0.46% to investors and pays a quarterly dividend of $0.03 per share. CureVac NV pays -- of its earnings as a dividend. Bayer AG pays out -5.13% of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BAYRY?
CureVac NV quarterly revenues are $543.2M, which are smaller than Bayer AG quarterly revenues of $12.5B. CureVac NV's net income of $371.8M is higher than Bayer AG's net income of -$357.1M. Notably, CureVac NV's price-to-earnings ratio is 4.29x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.33x versus 0.53x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.33x 4.29x $543.2M $371.8M BAYRYBayer AG0.53x -- $12.5B -$357.1M
-
Which has Higher Returns CVAC or BNTX?
BioNTech SE has a net margin of 68.44% compared to CureVac NV's net margin of -227.46%. CureVac NV's return on equity of 21.3% beat BioNTech SE's return on equity of -3.91%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M BNTXBioNTech SE54.16% -$1.82 $20.8B -
What do Analysts Say About CVAC or BNTX?
CureVac NV has a consensus price target of $6.24, signalling upside risk potential of 78.76%. On the other hand BioNTech SE has an analysts' consensus of $136.23 which suggests that it could grow by 46.85%. Given that CureVac NV has higher upside potential than BioNTech SE, analysts believe CureVac NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV2 2 0 BNTXBioNTech SE13 4 0 -
Is CVAC or BNTX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.347, suggesting its more volatile than the S&P 500 by 34.675%.
-
Which is a Better Dividend Stock CVAC or BNTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BNTX?
CureVac NV quarterly revenues are $543.2M, which are larger than BioNTech SE quarterly revenues of $192.3M. CureVac NV's net income of $371.8M is higher than BioNTech SE's net income of -$437.5M. Notably, CureVac NV's price-to-earnings ratio is 4.29x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.33x versus 7.52x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.33x 4.29x $543.2M $371.8M BNTXBioNTech SE7.52x 191.55x $192.3M -$437.5M
-
Which has Higher Returns CVAC or FMS?
Fresenius Medical Care AG has a net margin of 68.44% compared to CureVac NV's net margin of 3.1%. CureVac NV's return on equity of 21.3% beat Fresenius Medical Care AG's return on equity of 4.05%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M FMSFresenius Medical Care AG24.26% $0.27 $24.2B -
What do Analysts Say About CVAC or FMS?
CureVac NV has a consensus price target of $6.24, signalling upside risk potential of 78.76%. On the other hand Fresenius Medical Care AG has an analysts' consensus of $26.67 which suggests that it could fall by -6.05%. Given that CureVac NV has higher upside potential than Fresenius Medical Care AG, analysts believe CureVac NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV2 2 0 FMSFresenius Medical Care AG1 4 1 -
Is CVAC or FMS More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.616%.
-
Which is a Better Dividend Stock CVAC or FMS?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fresenius Medical Care AG offers a yield of 2.26% to investors and pays a quarterly dividend of $0.64 per share. CureVac NV pays -- of its earnings as a dividend. Fresenius Medical Care AG pays out 64.91% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CVAC or FMS?
CureVac NV quarterly revenues are $543.2M, which are smaller than Fresenius Medical Care AG quarterly revenues of $5.1B. CureVac NV's net income of $371.8M is higher than Fresenius Medical Care AG's net income of $159.1M. Notably, CureVac NV's price-to-earnings ratio is 4.29x while Fresenius Medical Care AG's PE ratio is 24.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.33x versus 0.80x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.33x 4.29x $543.2M $371.8M FMSFresenius Medical Care AG0.80x 24.86x $5.1B $159.1M
-
Which has Higher Returns CVAC or MKKGY?
Merck KGaA has a net margin of 68.44% compared to CureVac NV's net margin of 12.31%. CureVac NV's return on equity of 21.3% beat Merck KGaA's return on equity of 9.8%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M MKKGYMerck KGaA57.2% $0.33 $41.1B -
What do Analysts Say About CVAC or MKKGY?
CureVac NV has a consensus price target of $6.24, signalling upside risk potential of 78.76%. On the other hand Merck KGaA has an analysts' consensus of $37.10 which suggests that it could grow by 33.26%. Given that CureVac NV has higher upside potential than Merck KGaA, analysts believe CureVac NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV2 2 0 MKKGYMerck KGaA1 0 0 -
Is CVAC or MKKGY More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck KGaA has a beta of 0.992, suggesting its less volatile than the S&P 500 by 0.801%.
-
Which is a Better Dividend Stock CVAC or MKKGY?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck KGaA offers a yield of 1.8% to investors and pays a quarterly dividend of $0.50 per share. CureVac NV pays -- of its earnings as a dividend. Merck KGaA pays out 10.23% of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CVAC or MKKGY?
CureVac NV quarterly revenues are $543.2M, which are smaller than Merck KGaA quarterly revenues of $5.8B. CureVac NV's net income of $371.8M is lower than Merck KGaA's net income of $711M. Notably, CureVac NV's price-to-earnings ratio is 4.29x while Merck KGaA's PE ratio is 20.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.33x versus 2.64x for Merck KGaA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.33x 4.29x $543.2M $371.8M MKKGYMerck KGaA2.64x 20.08x $5.8B $711M
-
Which has Higher Returns CVAC or SMMNY?
Siemens Healthineers AG has a net margin of 68.44% compared to CureVac NV's net margin of 8.97%. CureVac NV's return on equity of 21.3% beat Siemens Healthineers AG's return on equity of 11.11%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M SMMNYSiemens Healthineers AG39.31% $0.25 $20.4B -
What do Analysts Say About CVAC or SMMNY?
CureVac NV has a consensus price target of $6.24, signalling upside risk potential of 78.76%. On the other hand Siemens Healthineers AG has an analysts' consensus of -- which suggests that it could fall by --. Given that CureVac NV has higher upside potential than Siemens Healthineers AG, analysts believe CureVac NV is more attractive than Siemens Healthineers AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV2 2 0 SMMNYSiemens Healthineers AG0 0 0 -
Is CVAC or SMMNY More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Siemens Healthineers AG has a beta of 1.060, suggesting its more volatile than the S&P 500 by 6.049%.
-
Which is a Better Dividend Stock CVAC or SMMNY?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Siemens Healthineers AG offers a yield of 3.79% to investors and pays a quarterly dividend of $0.50 per share. CureVac NV pays -- of its earnings as a dividend. Siemens Healthineers AG pays out 54.74% of its earnings as a dividend. Siemens Healthineers AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CVAC or SMMNY?
CureVac NV quarterly revenues are $543.2M, which are smaller than Siemens Healthineers AG quarterly revenues of $6.2B. CureVac NV's net income of $371.8M is lower than Siemens Healthineers AG's net income of $557.7M. Notably, CureVac NV's price-to-earnings ratio is 4.29x while Siemens Healthineers AG's PE ratio is 26.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.33x versus 2.39x for Siemens Healthineers AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.33x 4.29x $543.2M $371.8M SMMNYSiemens Healthineers AG2.39x 26.45x $6.2B $557.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
